HIVandHepatitis.com coverage of the 49th European Association for the Study of the Liver's International Liver Congress (EASL 2014) in London, April 9-13, 2014.
Conference highlights include new interferon-free treatments for hepatitis C, hepatitis B and delta, and management of liver disease complications such as cirrhosis and hepatocellular carcioma.
The World Health Organization (WHO) issued new guidelines for key populations affected by HIV/AIDS prior to the 20th International AIDS Conference held last week in Melbourne, Australia. Among the biggest changes -- and th eone that has garnered the most attention and controversy -- is a recommendation that gay men who are at risk for HIV infection should consider pre-exposure prophylaxis (PrEP) as an additional prevention option.
Interviews with participants in the U.S. sites of the iPrEx study of pre-exposure prophylaxis (PrEP) show that participants who took it mainly used it as an additional source of reassurance rather than to replace whatever risk-management strategy they were currently using to avoid HIV infection, researchers reported at the 20th International AIDS Conference last week in Melbourne.
People who switch away from their initial antiretroviral therapy (ART) regimen when their viral load is undetectable may have a higher likelihood of subsequent virological failure, researchers reported at the 20thInternational AIDS Conference last week in Melbourne. However, the association varied across groups and the researchers suggested their findings may reflect issues such as adherence difficulties or treatment changes due to pregnancy.